• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button Iconprivate equity

private equity

Page 34 of 100
CommentaryThe global M&A market’s big-deal bravado is losing steam as rates stay high in 2024
By Lucinda GuthrieJuly 23, 2024
NewslettersExclusive: Lauri Moore joins Bessemer as partner
By Allie GarfinkleJuly 22, 2024
empty chairs surround a brightly lit conference stage
NewslettersWhat GPs and LPs say to each other behind closed doors
By Allie GarfinkleJuly 19, 2024
NewslettersHow to communicate with Gen Z: “Be more vulnerable than you think you need to be”
By Allie GarfinkleJuly 18, 2024
Mark Suster, a partner at Upfront Ventures, spoke about A.I. on a panel at Fortune Brainstorm Tech 2024
FinanceVenture firms need to emulate private equity, says Upfront Ventures partner Mark Suster
By Luisa BeltranJuly 17, 2024
Marc Andreessen
PoliticsAndreessen Horowitz founders the latest to stake Trump, as tech money piles into his coffers
By Lizette Chapman, Bill Allison and BloombergJuly 16, 2024
NewslettersWhat you need to know about J.D. Vance’s VC career
By Allie GarfinkleJuly 16, 2024
FinancePrivate credit is growing into a $3.5 trillion industry: Meet 9 execs leading the way
By Luisa BeltranJuly 16, 2024
NewslettersA new credit card for NYC millionaires has over 30,000 people on the waitlist
By Allie GarfinkleJuly 15, 2024
NewslettersAI startups raised $24 billion globally in Q2, but the question remains: Where will value in AI accrue? Here’s one VC’s (slightly) contrarian take.
By Allie GarfinkleJuly 12, 2024
NewslettersExclusive: Armada lands $40 million in funding round led by Microsoft’s M12
By Allie GarfinkleJuly 11, 2024
A person using Ozempic on November 2, 2023, in Madrid, Spain. Novo Nordisk, the Danish firm that manufactures Ozempic, has reported record quarterly results, up almost 3% on the stock market. The company's revenues rose by 38% to DKK 58.73 billion, some 7.8 billion euros. Ozempic is a diabetic drug that causes a loss of up to 15% of body weight because it acts as an appetite suppressant, a side effect that has made the drug fashionable on social media as a weight loss drug.
NewslettersAs more and more weight-loss startups prescribe Ozempic and Wegovy, doctors say they’re making unproven claims
By Jessica Mathews and Alena BotrosJuly 10, 2024
FinanceGoldman Sachs’ CEO was seen as a dead man walking. A year later, the “David Solomon” era is being hailed as a success
By Luisa BeltranJuly 9, 2024
NewslettersExclusive: Canoe Intelligence raises $36 million for Series C led by Goldman Sachs
By Allie GarfinkleJuly 9, 2024
NewslettersHow whaling ventures in the 1800s shaped venture capital as we know it
By Allie GarfinkleJuly 8, 2024
1...
  • 32
  • 33
  • 34
  • 35
  • 36
...100
Most Popular
C-Suite
OpenAI’s Sam Altman says his highly disciplined daily routine has ‘fallen to crap’—and now unwinds on weekends at a ranch with no cell phone serviceAn image of a popular article
By Jacqueline MunisFebruary 5, 2026
Success
After decades in the music industry, Pharrell Williams admits he never stops working: ‘If you do what you love everyday, you’ll get paid for free'An image of a popular article
By Emma BurleighFebruary 3, 2026
Economy
Trump is giving the U.S. economy a $65 billion tax-refund shot in the arm, mostly for higher-income people, BofA saysAn image of a popular article
By Nick LichtenbergFebruary 5, 2026
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.